latanoprost and Vertigo

latanoprost has been researched along with Vertigo* in 1 studies

Trials

1 trial(s) available for latanoprost and Vertigo

Article	Year
Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2005, Volume: 133, Issue:3 To determine the short-term effects of latanoprost, a selective FP prostanoid receptor agonist, in Meniere's disease.. Latanoprost was administered by intratympanic injection once daily for 3 days. Before the first injection (day 1) and on days 5 and 15, hearing and tinnitus were determined. The patients assessed vertigo on a visual analogue scale on days 1-15. The study was randomized, double-blind, and placebo-controlled.. Latanoprost reduced vertigo/dysequilibrium around 30% (P < 0.05), and improved speech discrimination around 15% (P < 0.05). Tinnitus loudness deteriorated after injection of placebo (P < 0.01) but not after latanoprost. Side effects were few.. Latanoprost alleviated vertigo/dysequilibrium and improved hearing. The results indicate that the drug potentially could be useful for treatment of Meniere's disease. Topics: Adult; Double-Blind Method; Female; Hearing; Humans; Injections, Intralesional; Latanoprost; Male; Meniere Disease; Middle Aged; Pilot Projects; Prostaglandins F, Synthetic; Speech Perception; Treatment Outcome; Tympanic Membrane; Vertigo	2005

Article

Year

Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2005, Volume: 133, Issue:3

To determine the short-term effects of latanoprost, a selective FP prostanoid receptor agonist, in Meniere's disease.. Latanoprost was administered by intratympanic injection once daily for 3 days. Before the first injection (day 1) and on days 5 and 15, hearing and tinnitus were determined. The patients assessed vertigo on a visual analogue scale on days 1-15. The study was randomized, double-blind, and placebo-controlled.. Latanoprost reduced vertigo/dysequilibrium around 30% (P < 0.05), and improved speech discrimination around 15% (P < 0.05). Tinnitus loudness deteriorated after injection of placebo (P < 0.01) but not after latanoprost. Side effects were few.. Latanoprost alleviated vertigo/dysequilibrium and improved hearing. The results indicate that the drug potentially could be useful for treatment of Meniere's disease.

Topics: Adult; Double-Blind Method; Female; Hearing; Humans; Injections, Intralesional; Latanoprost; Male; Meniere Disease; Middle Aged; Pilot Projects; Prostaglandins F, Synthetic; Speech Perception; Treatment Outcome; Tympanic Membrane; Vertigo

2005